Relevance of Lower Airway Bacterial Colonization, Airway Inflammation, and Pulmonary Function in the Stable Stage of Chronic Obstructive Pulmonary Disease
Overview
Microbiology
Affiliations
The objective of this investigation was to verify the hypothesis that the presence of lower airway bacterial colonization (LABC) can be a stimulating factor of airway inflammation, more frequent exacerbation, and impact on pulmonary function, independent of current tobacco smoking in the stable phase of chronic obstructive pulmonary disease (COPD). A total of 46 ex-smokers with moderate to severe COPD, 19 healthy non-smokers, and 17 ex-smokers without COPD were included in this study. Their sputum specimens were collected at the first baseline visit and at the second visit after a follow-up of one year. The samples were analyzed for bacterial growth by culture, and the levels of interleukin (IL)-6, IL-8, and tumor necrosis factor alpha (TNF-α) were measured by enzyme-linked immunosorbent assay (ELISA). The frequencies of exacerbations and pulmonary function were compared at visit 2. At visit 1, 37.0% (17/46) were found to have LABC with bacterial loads ≥10⁶ CFU/ml in their sputum specimens. Haemophilus influenzae was the predominant pathogenic organism isolated. IL-8, IL-6, and TNF-α in these patients' sputum were significantly higher than those without LABC (p < 0.05). It was the presence of LABC that contributed to the significantly elevated IL-8 and IL-6 at the 1-year period (p < 0.05). LABC was also associated with significantly increased frequencies of exacerbations and declined forced expiratory volume in 1 s (FEV₁) (p < 0.05). LABC was documented in a subpopulation of stable COPD patients; it may be responsible for the deterioration of pulmonary function of COPD patients by promoting airway inflammation and/or increased frequency of exacerbations independently of tobacco smoking.
Metersky M, Dransfield M Am J Respir Crit Care Med. 2023; 208(12):1265-1267.
PMID: 37796579 PMC: 10765396. DOI: 10.1164/rccm.202308-1468VP.
Alsayed A, Abed A, Khader H, Al-Shdifat L, Hasoun L, Al-Rshaidat M Int J Mol Sci. 2023; 24(4).
PMID: 36835503 PMC: 9966333. DOI: 10.3390/ijms24044086.
Airway microbiome-immune crosstalk in chronic obstructive pulmonary disease.
Kayongo A, Robertson N, Siddharthan T, Ntayi M, Ndawula J, Sande O Front Immunol. 2023; 13:1085551.
PMID: 36741369 PMC: 9890194. DOI: 10.3389/fimmu.2022.1085551.
The Impact of Chronic Bronchial Infection in COPD: A Proposal for Management.
Martinez-Garcia M, Miravitlles M Int J Chron Obstruct Pulmon Dis. 2022; 17:621-630.
PMID: 35355582 PMC: 8958724. DOI: 10.2147/COPD.S357491.
Armitage M, Spittle D, Turner A Biomedicines. 2022; 10(1).
PMID: 35052762 PMC: 8773377. DOI: 10.3390/biomedicines10010081.